Is Risperdal Approved for Autism-Related Irritability?
Yes, risperidone (Risperdal) is FDA-approved for treating irritability associated with autistic disorder in children and adolescents aged 5 to 16 years. The approval, granted in 2006, targets symptoms like aggression, deliberate self-injury, and tantrums that interfere with daily functioning.[1][2]
How Does Risperdal Work for Autism Symptoms?
Risperdal is an atypical antipsychotic that blocks dopamine D2 and serotonin 5-HT2A receptors in the brain, reducing agitation and impulsive behaviors common in autism spectrum disorder. Clinical trials supporting approval showed significant reductions in irritability scores on the Aberrant Behavior Checklist (ABC) compared to placebo, with response rates around 69% versus 12%.[3][4]
What Do Clinical Studies Show?
Two pivotal 8-week, double-blind trials (one with 101 patients aged 5-17, another with 98) demonstrated risperdal's efficacy. Doses started at 0.25-0.5 mg/day, titrated to 1-2.5 mg/day based on weight. Improvements were seen within 1-2 weeks, sustained over 6 months in open-label extensions. Long-term data up to 3 years confirmed ongoing benefits but highlighted risks like weight gain.[2][5]
What Are the Common Side Effects and Risks?
Weight gain (up to 7.5% of body weight in trials), somnolence, fatigue, and increased prolactin levels are frequent. Serious risks include hyperglycemia, hyperlipidemia, tardive dyskinesia, and neuroleptic malignant syndrome. Pediatric patients face higher metabolic changes; monitoring of weight, blood sugar, lipids, and prolactin is required. It's not approved for adults with autism.[1][2]
Who Should Avoid Risperdal for Autism?
Avoid in patients with known hypersensitivity, dementia-related psychosis (increased mortality risk), or conditions worsened by prolactin elevation like prolactin-dependent tumors. Use caution with cardiovascular disease, seizures, or concurrent CYP2D6 inhibitors. It's pregnancy category C; weigh risks in breastfeeding.[1]
What Dosage and Administration Look Like?
Oral solution or tablets, starting low (0.25 mg/day for <20 kg, 0.5 mg/day for ≥20 kg), titrated every 2 weeks to target 0.5-3 mg/day. No adjustment needed for mild renal/hepatic impairment, but avoid in severe cases. Discontinue gradually to prevent withdrawal.[2]
How Does It Compare to Other Treatments?
Risperdal outperformed placebo and rivals aripiprazole (Abilify, also FDA-approved for this use). Behavioral therapies like Applied Behavior Analysis remain first-line; antipsychotics are for severe cases unresponsive to them. Off-label options include SSRIs or mood stabilizers, but evidence is weaker.[4][6]
When Did Approval Happen and What's the Status?
Approved October 2006 based on NIMH-funded studies. Generic risperidone available since 2008 patent expiry; check DrugPatentWatch.com for formulation-specific patents.[7][1]
[1]: FDA Label for Risperdal (Janssen, 2023). https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/020272s077lbl.pdf
[2]: FDA Approval Summary (2006). https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-risperdal-children-irritability-associated-autistic-disorder
[3]: McCracken et al., NEJM (2002). https://www.nejm.org/doi/full/10.1056/NEJMoa013171
[4]: Marcus et al., J Am Acad Child Adolesc Psychiatry (2009).
[5]: Correll et al., JAMA (2009).
[6]: AAP Guidelines on Autism (2019).
[7]: DrugPatentWatch.com. https://www.drugpatentwatch.com/p/tradename/RISPERDAL